| Table 1. Contemporary Classification of GLP1RAs. | ||
| MONOFORMULATIONS | ||
|---|---|---|
| ROUTE | INDICATION | |
| Type 2 Diabetes mellitus | Obesity | |
| Oral | Semaglutide 3,7,14mg Semaglutide 25-50mg Danuglipron |
Semaglutide 50mg Danuglipron (in develop) |
| Subcutaneous daily | Lixisenatide, Liraglutide 0.6-1.8mg | Liraglutide 3.0mg |
| Subcutaneous weekly | Exenatide LAR, Dulaglutide, Semaglutide 0.25-1.0mg | Semaglutide 2.4mg |
| Implantable | ITCA 650 I (discontinued) | |
| CO-FORMULATIONS | ||
| ROUTE | CONTENT | |
| GLP1RA + insulin | GLP1RA + other agonist | |
| Subcutaneous daily | IDegLira; LixiLan | |
| Subcutaneous weekly | IcoSemaa | Sema-Amylin HM15211 |
| Tirzepatide 5, 10, 15mg | ||
From: Kalra S, Bhattacharya S, Kapoor N. Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists. Diabetes Ther. 2021;12:2133-47.